Credit outlook: Markets already have the vaccine

Credit outlook: Markets already have the vaccine

29-09-2020 | Quarterly outlook
The world is waiting for a vaccine that will enable us to return to our normal lives. The market already got its shot, though.
  • James Stuttard
    Head of Global Macro team and Portfolio Manager
  • Sander  Bus
    Co-head Credit team
  • Victor  Verberk
    CIO Fixed Income and Sustainability

Speed read

  • Central banks have so far immunized markets against negative macro news
  • Markets are too complacent and are trading at rich valuations
  • Rally has run its course, but volatility will offer opportunities from time to time

We are still in the midst of the largest global health crisis seen in a century, and the world is waiting for a vaccine that will enable us to return to our normal lives. The market has already had its shot, though, in the form of unprecedented monetary and fiscal support for the private sector. The big question is if the immunity to negative news will last in the run-up to the US elections, and will survive the Brexit negotiations, geo-political tensions and the latest rise in Covid-19 infections.

Figure 1 | Market cycle: Mapping our view on market segments

Source: Robeco, September 2020

In light of the massive gap between markets and fundamentals, we approached this Credit Quarterly Outlook with the question: do fundamentals still matter?

Sander Bus, Co-head of the Robeco Credit team, says, “In the longer term, we have no doubt that fundamentals still matter for markets but, for the last several months, the central bank put has overwhelmed everything else. Quick and decisive action by governments and central banks helped to restore a large part of the initial losses, by removing the systemic risk in the market. The risk of a banking crisis or even a Eurozone sovereign crisis is now arguably lower than before Covid-19, due to the easing of banking regulation, the introduction of quasi Eurobonds, relaxed rules for state support and several other supportive actions by authorities”.

We recognize this dynamic and feel comfortable that at least senior bank and Eurozone sovereign spreads are under policy control and unlikely to move dramatically wider. The same holds for higher-quality corporate bonds that are eligible for ECB buying and that can benefit from fiscal support in the form of guaranteed lending, furlough schemes and other measures.

According to Bus, “one of the few segments of the market where fundamentals still matter today is the weaker end of the high yield market. Here you find many vulnerable companies that will not survive an extended period of weak demand”.

Stay informed on our latest insights with monthly mail updates
Stay informed on our latest insights with monthly mail updates

Limited inflationary impact

Victor Verberk, Co-head of the Robeco Credit team, sees limited inflationary consequences from the policy response. “We do not expect much inflationary impact from the massive increase in money supply engineered by fiscal authorities and central banks, at least in the next few years. The disinflationary forces stemming from the disruption to demand will simply be too strong. Secular forces such as aging and technological developments do not point to galloping inflation, either. Moreover, academic research suggests that the inflationary impact of deglobalization should not be overestimated”.

The odds of an inflationary uptick on a horizon beyond the coming years do seem more pronounced, though. Nevertheless, this would require the increase in money supply to be sustained and eventually associated with much stronger consumer and business spending, as ‘more money starts to chase fewer goods’.

Inflation will probably follow the rules of the ‘ketchup theory’, says Verberk: “At first, nothing comes out of the bottle, but as you keep on shaking and the ketchup starts to flow, you end up with more than you wanted.”

Fading recovery momentum

So, where are we now? After the initial shock, macro data in Q3 surprised to the upside compared to very downbeat expectations. This has helped risk markets. But the momentum of the recovery is clearly fading now and the positive surprises have ended. With winter approaching in the northern hemisphere, we are already seeing more infections across much of Europe and local lockdowns that will hurt the economic recovery.

For many corporates, the economic downturn means weaker balance sheets and negative cashflow. “Let’s not forget that Covid-19 arrived after the longest US economic expansion ever recorded by the NBER,” says Robeco Credit Strategist Jamie Stuttard. “We were already warning of an economic downturn in the Outlook a year ago, not knowing that Covid-19 would be the trigger.”

“Weaknesses such as stretched balance sheets, debt-funded M&A and poor documentation were already prevalent in corporate credit. Massive government intervention in the private sector and liquidity injections helped to extend the cycle but it is likely (and healthy!) that we go through a proper bear market. A bear market is the best medicine to clean up the house; it gets rid of zombie firms, repairs balance sheets, and strengthens documentation. Only when that process is finalized are the markets ready for a brand new multi-year credit bull market,” says Stuttard.

Stretched valuations

“For the market as a whole we judge valuations as being stretched,” says Verberk. “Spread levels are at or below the long-term average for all segments of the market. The tight spreads can be explained by the strong technicals but do not compensate for the current fundamental environment.”

He adds that the market looks even more expensive if adjusted for quality. “The weight of BBB in the US investment grade market has steadily gone up from 35% in 2008 to over 50% today, within 0.5% of its all-time record.”

For high yield, it is easier to see spreads going wider from here, explains Bus, since this market only benefits indirectly from the central bank put. “The Fed limits individual high yield bond buying to companies that were investment grade before late March 2020, a sum total of just eight tickers.”

The rally may have run its course

“We now hold the view that the rally has run its course,” says Bus. “It is difficult to see further material spread tightening from here. We lower our beta for investment grade to 1. For high yield, where we were already below 1, we keep it there.”

We are convinced that there will be opportunities to add or reduce risk in the coming months, not only from a top-down perspective but also in individual issuers or sectors. There is still a lot of volatility in Covid-sensitive sectors, which from time to time offer good value.


Disclaimer Robeco Switzerland Ltd.

The information contained on these pages is for marketing purposes and solely intended for Qualified Investors in accordance with the Swiss Collective Investment Schemes Act of 23 June 2006 (“CISA”) domiciled in Switzerland, Professional Clients in accordance with Annex II of the Markets in Financial Instruments Directive II (“MiFID II”) domiciled in the European Union und European Economic Area with a license to distribute / promote financial instruments in such capacity or herewith requesting respective information on products and services in their capacity as Professional Clients. 

The Funds are domiciled in Luxembourg and The Netherlands. ACOLIN Fund Services AG, postal address: Affolternstrasse 56, 8050 Zürich, acts as the Swiss representative of the Fund(s). UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zurich, postal address: Europastrasse 2, P.O. Box, CH-8152 Opfikon, acts as the Swiss paying agent. The prospectus, the Key Investor Information Documents (KIIDs), the articles of association, the annual and semi-annual reports of the Fund(s) may be obtained, on simple request and free of charge, at the office of the Swiss representative ACOLIN Fund Services AG. The prospectuses are also available via the website www.robeco.ch. Some funds about which information is shown on these pages may fall outside the scope of the Swiss Collective Investment Schemes Act of 26 June 2006 (“CISA”) and therefore do not (need to) have a license from or registration with the Swiss Financial Market Supervisory Authority (FINMA). 

Some funds about which information is shown on this website may not be available in your domicile country. Please check the registration status in your respective domicile country. To view the RobecoSwitzerland Ltd. products that are registered/available in your country, please go to the respective Fund Selector, which can be found on this website and select your country of domicile. 

Neither information nor any opinion expressed on this website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco Switzerland Ltd. product should only be made after reading the related legal documents such as management regulations, prospectuses, annual and semi-annual reports. 

By clicking “I agree” you confirm that you/the company you represent falls under one of the above-mentioned categories of addressees and that you have read, understood and accept the terms of use for this website.

I Disagree